Sleep disturbances are highly prevalent in cancer patients and remain significantly underrecognized in oncologic critical care. Across the cancer continuum, up to 90–95% of patients report disrupted sleep patterns, particularly during active treatment and critical illness phases (Büttner-Teleagă et al., Int J Environ Res Public Health 18:11696, 2021; Han et al., Front Oncol 15:1535442, 2025). Sleep disruption arises from multifactorial etiologies, including tumor-related inflammation, treatment side effects, psychological stress, and environmental factors intrinsic to the intensive care unit (ICU). Emerging evidence further links circadian dysregulation and neuroinflammation to adverse outcomes, including impaired immune surveillance, poor functional recovery, and reduced overall survival (Fishbein et al., J Clin Invest 131:e148286, 2021). ICU admission amplifies these disturbances through continuous light exposure, nocturnal caregiving, sedative use, and loss of circadian cues. Sleep disturbance in this context is linked to poorer functional status, greater symptom burden, diminished quality of life, prolonged recovery, and potentially higher mortality (Davis et al., Sleep Med 108:124–136, 2023). The optimal management of sleep disorders in this vulnerable group requires regular assessment and systematic intervention, including non-pharmacological and tailored pharmacologic therapies (Han et al., Front Oncol 15:1535442, 2025; Balachandran et al., Curr Treat Options Oncol 22:81, 2021). Treatment of sleep problems in these patients may improve the morbidity and possibly mortality associated with cancer.